Yayın: Ferritin / albumin ratio could be a new indicator of COVID-19 disease mortality
| dc.contributor.author | Taşkin, Öztürk | |
| dc.contributor.author | Yilmaz, Ayşe | |
| dc.contributor.author | Soylu, Veysel Garani | |
| dc.contributor.author | Demir, Ufuk | |
| dc.contributor.author | Çatan Inan, Funda | |
| dc.date.accessioned | 2026-01-04T18:21:41Z | |
| dc.date.issued | 2023-01-31 | |
| dc.description.abstract | Introduction: Despite significant advances in the management of patients with COVID-19, there is a need for markers to guide treatment and predict disease severity. In this study, we aimed to evaluate the relationship of the ferritin/albumin (FAR) ratio with disease mortality. Methodology: Acute Physiology and Chronic Health Assessment II scores and laboratory results of patients diagnosed with severe COVID-19 pneumonia were retrospectively analyzed. The patients were divided into two groups: survivors and non-survivors. Data for ferritin, albumin, and ferritin/albumin ratio among COVID-19 patients were analyzed and compared. Results: The mean age was higher in non-survivors (p = 0.778, p < 0.001, respectively). The ferritin/albumin ratio was significantly higher in the non-survival group (p < 0.05). Taking the cut-off value of the ferritin/albumin ratio of 128.71 in the ROC analysis, it predicted the critical clinical status of COVID-19 with 88.4% sensitivity and 88.4% specificity. Conclusions: ferritin/albumin ratio is a practical, inexpensive, and easily accessible test that can be used routinely. In our study, the ferritin/albumin ratio has been identified as a potential parameter in determining the mortality of critically ill COVID-19 patients treated in intensive care. | |
| dc.description.uri | https://doi.org/10.3855/jidc.17409 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/36795927 | |
| dc.description.uri | https://doaj.org/article/85726735c43a4ce89e537e8384dea163 | |
| dc.identifier.doi | 10.3855/jidc.17409 | |
| dc.identifier.eissn | 1972-2680 | |
| dc.identifier.endpage | 42 | |
| dc.identifier.openaire | doi_dedup___::477a63ed1c0212925285652ae5ce385d | |
| dc.identifier.orcid | 0000-0001-7328-9579 | |
| dc.identifier.orcid | 0000-0001-7635-0830 | |
| dc.identifier.orcid | 0000-0002-4617-3367 | |
| dc.identifier.orcid | 0000-0002-0596-8948 | |
| dc.identifier.orcid | 0000-0003-3974-7577 | |
| dc.identifier.pubmed | 36795927 | |
| dc.identifier.scopus | 2-s2.0-85148258736 | |
| dc.identifier.startpage | 37 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/40480 | |
| dc.identifier.volume | 17 | |
| dc.identifier.wos | 000937140200005 | |
| dc.publisher | Journal of Infection in Developing Countries | |
| dc.relation.ispartof | The Journal of Infection in Developing Countries | |
| dc.rights | OPEN | |
| dc.subject | Critical Care | |
| dc.subject | Albumin | |
| dc.subject | ferritin | |
| dc.subject | COVID-19 | |
| dc.subject | Prognosis | |
| dc.subject | mortality | |
| dc.subject | RC31-1245 | |
| dc.subject | Microbiology | |
| dc.subject | QR1-502 | |
| dc.subject | ferritin/albumin ratio | |
| dc.subject | ROC Curve | |
| dc.subject | Albumins | |
| dc.subject | Ferritins | |
| dc.subject | Humans | |
| dc.subject | predictive | |
| dc.subject | Internal medicine | |
| dc.subject | Retrospective Studies | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Ferritin / albumin ratio could be a new indicator of COVID-19 disease mortality | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Öztürk Taşkin","name":"Öztürk","surname":"Taşkin","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0001-7328-9579"},"provenance":null}},{"fullName":"Ayşe Yilmaz","name":"Ayşe","surname":"Yilmaz","rank":2,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0001-7635-0830"},"provenance":null}},{"fullName":"Veysel Garani Soylu","name":"Veysel Garani","surname":"Soylu","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0002-4617-3367"},"provenance":null}},{"fullName":"Ufuk Demir","name":"Ufuk","surname":"Demir","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0002-0596-8948"},"provenance":null}},{"fullName":"Funda Çatan Inan","name":"Funda","surname":"Çatan Inan","rank":5,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3974-7577"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"und","label":"Undetermined"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Critical Care"},"provenance":null},{"subject":{"scheme":"keyword","value":"Albumin"},"provenance":null},{"subject":{"scheme":"keyword","value":"ferritin"},"provenance":null},{"subject":{"scheme":"keyword","value":"COVID-19"},"provenance":null},{"subject":{"scheme":"keyword","value":"Prognosis"},"provenance":null},{"subject":{"scheme":"keyword","value":"mortality"},"provenance":null},{"subject":{"scheme":"keyword","value":"RC31-1245"},"provenance":null},{"subject":{"scheme":"keyword","value":"Microbiology"},"provenance":null},{"subject":{"scheme":"keyword","value":"QR1-502"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"ferritin/albumin ratio"},"provenance":null},{"subject":{"scheme":"keyword","value":"ROC Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Albumins"},"provenance":null},{"subject":{"scheme":"keyword","value":"Ferritins"},"provenance":null},{"subject":{"scheme":"keyword","value":"Humans"},"provenance":null},{"subject":{"scheme":"keyword","value":"predictive"},"provenance":null},{"subject":{"scheme":"keyword","value":"Internal medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Retrospective Studies"},"provenance":null}],"mainTitle":"Ferritin / albumin ratio could be a new indicator of COVID-19 disease mortality","subTitle":null,"descriptions":["<jats:p>Introduction: Despite significant advances in the management of patients with COVID-19, there is a need for markers to guide treatment and predict disease severity. In this study, we aimed to evaluate the relationship of the ferritin/albumin (FAR) ratio with disease mortality. Methodology: Acute Physiology and Chronic Health Assessment II scores and laboratory results of patients diagnosed with severe COVID-19 pneumonia were retrospectively analyzed. The patients were divided into two groups: survivors and non-survivors. Data for ferritin, albumin, and ferritin/albumin ratio among COVID-19 patients were analyzed and compared. Results: The mean age was higher in non-survivors (p = 0.778, p < 0.001, respectively). The ferritin/albumin ratio was significantly higher in the non-survival group (p < 0.05). Taking the cut-off value of the ferritin/albumin ratio of 128.71 in the ROC analysis, it predicted the critical clinical status of COVID-19 with 88.4% sensitivity and 88.4% specificity. Conclusions: ferritin/albumin ratio is a practical, inexpensive, and easily accessible test that can be used routinely. In our study, the ferritin/albumin ratio has been identified as a potential parameter in determining the mortality of critically ill COVID-19 patients treated in intensive care.</jats:p>"],"publicationDate":"2023-01-31","publisher":"Journal of Infection in Developing Countries","embargoEndDate":null,"sources":["Crossref","Journal of Infection in Developing Countries, Vol 17, Iss 01 (2023)"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"The Journal of Infection in Developing Countries","issnPrinted":null,"issnOnline":"1972-2680","issnLinking":null,"ep":"42","iss":null,"sp":"37","vol":"17","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::477a63ed1c0212925285652ae5ce385d","originalIds":["10.3855/jidc.17409","50|doiboost____|477a63ed1c0212925285652ae5ce385d","36795927","oai:doaj.org/article:85726735c43a4ce89e537e8384dea163","50|doajarticles::185e283d4783024a5f23abeaa424fd3e"],"pids":[{"scheme":"doi","value":"10.3855/jidc.17409"},{"scheme":"pmid","value":"36795927"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":10,"influence":3.0339093e-9,"popularity":1.0083608e-8,"impulse":10,"citationClass":"C5","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.3855/jidc.17409"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.3855/jidc.17409"],"publicationDate":"2023-01-31","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"36795927"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.3855/jidc.17409"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/36795927"],"publicationDate":"2023-02-22","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3855/jidc.17409"}],"type":"Article","urls":["https://doaj.org/article/85726735c43a4ce89e537e8384dea163"],"publicationDate":"2023-01-01","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
